Taveira-DaSilva et al. [9] observed that the effects of sirolimus on VEGF-D levels and DLCO were especially marked in patients with LAM with lymphatic involvement than those without lymphatic involvement. Here, VEGFD is linked to lymphangioleiomyomatosis.